Pulmatrix (NASDAQ: PULM) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ: PULM – Get Rating) in a research report issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $ 10.00 price target (up previously from $ 5.00) on shares of Pulmatrix in a research note on Wednesday, March 30th.

Shares of PULM opened at $ 4.50 on Friday. The stock has a 50-day moving average of $ 4.92 and a two-hundred day moving average of $ 6.35. Pulmatrix has a one year low of $ 4.03 and a one year high of $ 20.80.

Pulmatrix (NASDAQ: PULM – Get Rating) last issued its quarterly earnings results on Thursday, May 12th. The biotechnology company reported ($ 1.51) EPS for the quarter, missing analysts’ consensus estimates of ($ 1.41) by ($ 0.10). Pulmatrix had a negative return on equity of 37.38% and a negative net margin of 426.00%. The firm had revenue of $ 1.16 million for the quarter, compared to analyst estimates of $ 1.07 million. As a group, equities research analysts expect that Pulmatrix will post -6.04 earnings per share for the current year.

A hedge fund recently bought a new stake in Pulmatrix stock. Parallax Volatility Advisers LP acquired a new position in shares of Pulmatrix, Inc. (NASDAQ: PULM – Get Rating) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 97,919 shares of the biotechnology company’s stock, valued at approximately $ 43,000. Parallax Volatility Advisers LP owned 0.17% of Pulmatrix at the end of the most recent quarter.

Pulmatrix Company Profile (Get Rating)

Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

Featured Stories

Receive News & Ratings for Pulmatrix Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pulmatrix and related companies with MarketBeat.com’s FREE daily email newsletter.


Leave a Reply

Your email address will not be published.

Back to top button